(Q38945162)

7 September 2017

1 reference

title

Ponatinib in the therapy of chronic myeloid leukemia (English)

1 reference

7 September 2017

main subject

chronic myeloid leukemia

0 references

1 reference

Marc Poch Martell

1

1 reference

7 September 2017

Hassan Sibai

series ordinal

2

1 reference

7 September 2017

Uday Deotare

series ordinal

3

1 reference

7 September 2017

Jeffrey H Lipton

series ordinal

4

1 reference

7 September 2017

language of work or name

1 reference

2 September 2016

1 reference

Expert Review of Hematology

7 September 2017

published in

1 reference

7 September 2017

volume

9

1 reference

7 September 2017

issue

10

1 reference

7 September 2017

page(s)

923-932

1 reference

The age incidence of chronic myeloid leukemia can be explained by a one-mutation model

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Effects of food on the pharmacokinetics of ponatinib in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17474086.2016.1232163

10.1080/17474086.2016.1232163

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference